OBS-LIVER-F4407Active studySynthetic mock data
Multi-modality surveillance of cirrhotic cohort
Time-to-HCC detection
Phase
Observational
Enrollment
612/800
77%
Sites
22
Readout
2027-12
Waterfall — best % change in target-lesion sum (OBS-LIVER-F4407)
Per-subject best response from baseline. Sorted descending. Reference lines at PR (-30%) and PD (+20%) thresholds.
CR (0)PR (0)SD (4)PD (0)
4 subjects, sorted by best responseDrill into study →
Protocol summary
- Sponsor
- Vanq Population Health
- Status
- active
- Start date
- 2023-11-01
- Arms
- 1
- Sites
- 22
- Primary endpoint
- Time-to-HCC detection
Endpoints assigned to this study
Subjects in OBS-LIVER-F4407
4 subjects with serial RECIST measurements
Featured subject
Kenji Tanaka · s-4407-208 · MRN 6026508
RECIST 1.1 — Target lesions
Serial measurements (mm) and per-visit response
Sum-of-diameters; % from baseline (PR ≤ -30%); % from nadir (PD ≥ +20% absolute ≥ 5 mm)
| Lesion | Modality | Baseline2024-06-01 | Q12024-09-01 | Q22024-12-01 | Q32025-03-01 | Q42025-06-01 |
|---|---|---|---|---|---|---|
Liver segment 4 nodule | MRI | 14 | 16 | 18 | 20 | 22 |
| Sum of diameters | mm | 14 | 16 | 18 | 20 | 22 |
| % from baseline | 0.0% | +14.3% | +28.6% | +42.9% | +57.1% | |
| % from nadir | 0.0% | +14.3% | +28.6% | +42.9% | +57.1% | |
| RECIST response | NE | SD | SD | SD | PD |
Non-target lesions
Per-visit qualitative status (presence / absence / equivocal / new)
| Lesion | Baseline | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|---|
| Portal hypertension | present | present | present | present | present |
Cohorts in OBS-LIVER-F4407
Cross-links